Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMM910 in Postmenopausal Osteoporosis
NCT06949137Phase 1Active, not recruiting
- Sponsor
- Help Therapeutics
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HMM910 in osteoporosis (3 arms), sponsored by Help Therapeutics. Primary endpoint: Incidence and Severity of Treatment-Related Adverse Events at 4 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
HMM910
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06949137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949137.